{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000130","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.199393+00:00","generated_at":"2026-06-09T23:36:03.044455+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xeris raises year-end cash guidance to $65-70M, tightens 2023 revenue to $155-165M","bullets":["Year-end cash, equivalents, and short-term investments guided to $65-70M (up from $55-65M).","Full-year 2023 total revenue guidance tightened to $155-165M from $145-165M.","Received $6M milestone payment from Amgen for subcutaneous TEPEZZA formulation success.","Company reaffirms cash flow breakeven in Q4 2023; net cash outflow H2 expected ~$11-16M.","Q3 2023 earnings call scheduled for November 9, 2023 at 8:30 a.m. ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000130","json":"https://secwatch.observer/filing/0001867096-23-000130.json","markdown":"https://secwatch.observer/filing/0001867096-23-000130.md","text":"https://secwatch.observer/filing/0001867096-23-000130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000130/0001867096-23-000130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000130/xers-20231016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:36:03.044455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}